{"drugs":["Factor XIII Recombinant","Tretten"],"mono":{"0":{"id":"930407-s-0","title":"Generic Names","mono":"Factor XIII Recombinant"},"1":{"id":"930407-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930407-s-1-4","title":"Adult Dosing","mono":"<b>Bleeding; Prophylaxis - Hereditary factor XIII A subunit deficiency:<\/b> 35 international units\/kg slow IV bolus (not to exceed 1 to 2 mL\/minute) once monthly; consider dose adjustment if target trough levels of factor XIII activity of 10% or more are not reached "},"1":{"id":"930407-s-1-5","title":"Pediatric Dosing","mono":"<b>Bleeding; Prophylaxis - Hereditary factor XIII A subunit deficiency:<\/b> 35 international units\/kg slow IV bolus (not to exceed 1 to 2 mL\/minute) once monthly; consider dose adjustment if target trough levels of factor XIII activity of 10% or more are not reached "},"3":{"id":"930407-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Bleeding; Prophylaxis - Hereditary factor XIII A subunit deficiency<br\/>"}}},"3":{"id":"930407-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930407-s-3-9","title":"Contraindications","mono":"hypersensitivity to recombinant coagulation factor XIII or any component of the product <br\/>"},{"id":"930407-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions, including anaphylactic reactions, may occur; discontinue use immediately if suspected<\/li><li>inhibitory antibodies may develop; if inhibitors are suspected with a lack of therapeutic response (evidenced by bleeding or lab findings of factor XIII activity that does not reach expected levels), test for antibodies<\/li><li>pediatric patients; adverse events were reported more frequently than in adults<\/li><li>thromboembolism may occur; monitoring recommended for those with predisposition for thrombosis<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930407-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930407-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930407-s-4","title":"Drug Interactions","sub":{"1":{"id":"930407-s-4-14","title":"Major","mono":"<ul>Coagulation Factor VIIa (theoretical)<\/ul>"}}},"5":{"id":"930407-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (1% or greater)<\/li><li><b>Hematologic:<\/b>Elevated D-dimer level (1% or greater)<\/li><li><b>Immunologic:<\/b>Antibody development, Non-neutralizing (5.2%)<\/li><li><b>Musculoskeletal:<\/b>Pain in limb (1% or greater)<\/li><li><b>Neurologic:<\/b>Headache (1% or greater)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"930407-s-6","title":"Drug Name Info","sub":{"0":{"id":"930407-s-6-17","title":"US Trade Names","mono":"Tretten<br\/>"},"2":{"id":"930407-s-6-19","title":"Class","mono":"Hemostatic<br\/>"},"3":{"id":"930407-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930407-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930407-s-7","title":"Mechanism Of Action","mono":"Recombinant coagulation factor XIII A-subunit is a recombinant human factor XIII-A(2) homodimer composed of 2 factor XIII A-subunits. Recombinant coagulation factor XIII A-subunit binds to free human factor XIII B-subunit and is activated by thrombin in the presence of calcium; once active, it increases the mechanical strength of fibrin clots, retards fibrinolysis, and enhances platelet adhesion to the site of injury in a dose-dependent manner.<br\/>"},"8":{"id":"930407-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930407-s-8-24","title":"Distribution","mono":"Vd: 61.2 to 65.9 mL\/kg <br\/>"},"3":{"id":"930407-s-8-26","title":"Excretion","mono":"Total Body Clearance: 0.33 to 0.41 mL\/hr\/kg <br\/>"},"4":{"id":"930407-s-8-27","title":"Elimination Half Life","mono":"5.1 to 7.1 days <br\/>"}}},"9":{"id":"930407-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>bring powder and provided diluent to a temperature of not more than 25 degrees C (77 degrees F)<\/li><li>reconstitute powder with provided diluent and gently swirl until powder is dissolved; do not aim stream of diluent directly at powder and do not shake vial<\/li><li>reconstituted solution may be diluted further with 0.9% sodium chloride for administration of small doses<\/li><li>may be stored refrigerated or at room temperature for up to 3 hours<\/li><li>administer as a slow bolus IV injection at a rate not exceeding 1 to 2 mL\/minute; do not give as an IV drip<\/li><\/ul>"},"10":{"id":"930407-s-10","title":"Monitoring","mono":"<ul><li>trough factor XIII activity levels, using a validated assay, to obtain an activity level of 10% or higher<\/li><li>fewer bleeding episodes may indicate clinical efficacy<\/li><li>factor XIII inhibitory antibody concentration assay, in patients with lower than expected plasma activity levels or uncontrolled bleeding<\/li><li>signs and symptoms of thrombosis, in patients with conditions that predispose them to thrombosis<\/li><\/ul>"},"11":{"id":"930407-s-11","title":"How Supplied","mono":"<b>Tretten<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/>"},"13":{"id":"930407-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include headache, pain in the extremities, and injection site pain.<\/li><li>Instruct patient to report signs\/symptoms of anaphylaxis or hypersensitivity reactions (urticaria, rash, tightness of chest, wheezing, hypotension).<\/li><li>Advise patient to report signs\/symptoms of thrombosis (eg, limb or abdomen swelling and\/or pain, chest pain, shortness of breath, loss of sensation or motor power, altered consciousness, vision, or speech).<\/li><li>Tell patient to report breakthrough bleeding.<\/li><\/ul>"}}}